comparemela.com

Latest Breaking News On - Oligonucleotide discovery - Page 1 : comparemela.com

Silence Therapeutics plc (NASDAQ:SLN) Holdings Boosted by Parkman Healthcare Partners LLC

Parkman Healthcare Partners LLC raised its stake in Silence Therapeutics plc (NASDAQ:SLN – Free Report) by 20.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 232,942 shares of the company’s stock after acquiring an additional 40,063 shares during the period. Parkman […]

Silence-therapeutics-company-profile
Nasdaq
Morgan-stanley
Vivo-capital
Securities-exchange-commission
Sg-americas-securities
Parkman-healthcare-partners
Silence-therapeutics
Free-report
Healthcare-partners
Get-free-report

Silence Therapeutics (OTCMKTS:SLNCF) Stock Price Up 1.3%

Silence Therapeutics plc (OTCMKTS:SLNCF – Get Free Report) rose 1.3% during mid-day trading on Thursday . The company traded as high as $7.60 and last traded at $7.60. Approximately 698 shares traded hands during mid-day trading, a decline of 40% from the average daily volume of 1,171 shares. The stock had previously closed at $7.50. […]

Silence-therapeutics-company-profile
Silence-therapeutics
Get-free-report
Oligonucleotide-discovery
Silence-therapeutics-daily

Silence Therapeutics (OTCMKTS:SLNCF) Trading 1.3% Higher

Shares of Silence Therapeutics plc (OTCMKTS:SLNCF – Get Free Report) shot up 1.3% during mid-day trading on Thursday . The stock traded as high as $7.60 and last traded at $7.60. 698 shares were traded during trading, a decline of 40% from the average session volume of 1,171 shares. The stock had previously closed at […]

Silence-therapeutics-company-profile
Silence-therapeutics
Get-free-report
Oligonucleotide-discovery
Silence-therapeutics-daily

Silence Therapeutics (NASDAQ:SLN) Receives "Buy" Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Silence Therapeutics (NASDAQ:SLN – Free Report) in a research note released on Friday, Benzinga reports. HC Wainwright currently has a $75.00 price objective on the stock. Several other research firms have also commented on SLN. BMO Capital Markets initiated coverage on Silence Therapeutics in a research […]

Parkman-healthcare-partners
Vivo-capital
Sg-americas-securities
Janus-henderson-group
Morgan-stanley
Silence-therapeutics
Free-report
Chardan-capital
Get-free-report
Healthcare-partners
Oligonucleotide-discovery

Silence Therapeutics (LON:SLN) Share Price Passes Above Two Hundred Day Moving Average of $535.00

Silence Therapeutics plc (LON:SLN – Get Free Report)’s share price passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of GBX 535 ($6.80) and traded as high as GBX 546 ($6.94). Silence Therapeutics shares last traded at GBX 535 ($6.80), with a […]

Silence-therapeutics
Get-free-report
Oligonucleotide-discovery
Silence-therapeutics-daily

vimarsana © 2020. All Rights Reserved.